Goldman Sachs Group Inc is facing tough time in selling $2.8 billion of debt in the wake of ongoing drug pricing controversy in the pharmaceutical industry.
Amdipharm Mercury
Breaking News
- IBM's Acquisition of HashiCorp for $6.4 Billion Confirmed, Aimed at Strengthening Cloud Capabilities
- Apple's Vision Pro Production Slashed as Demand Falls Short: Report
- TikTok Voluntarily Suspends New App's Task and Reward Program After EU Regulators Express Concern Over Addictive Effects Among Young Users
Subscribe to VCpost newsletter
Most Popular
- Doctors Raise Concerns Over Proposed Capital Gains Tax Changes
- Where's My Child Tax Credit 2024: When to Receive My Money After April 15 Tax Filing Deadline?
- Celebrity Designer Nancy Gonzalez Jailed for Smuggling Crocodile, Python Handbags
- IBM Set to Acquire HashiCorp in Possible Mega-Deal, Stock Skyrockets 24% to $6.1 Billion Valuation
- Kroger and Albertsons to Sell off 166 Stores in Effort to Gain Approval for Their $25 Billion Merger
- How to Get IRS Unclaimed Tax Refunds: Here's What to Do If You Think You Have Pending Payments
- Student Loan Forgiveness Processing for This Group of Borrowers Will Stop Next Week
- Stellantis Plans to Lay Off Unspecified Number of Workers at US Factories in Coming Months
